WinearlsC.G., OliverD.O., PippardM.J., ReidC., DowningM.R., CotesP.M.Effect of erythropoietin derived from recombinant DNA on the anaemia of patients maintained by haemodialysis.Lancet1986; 2: 1175–8.
2.
EschbachJ.W., EgrieJ.C., DowningM.R., BrownJ.K., AdamsonJ.W.Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial.N Engl J Med1987; 316: 73–8.
3.
EschbachJ.W., AbdulhadiM.H., BrownJ.K., DelanoB.G., DowningM.R., EgrieJ.C.Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.Ann Intern Med1989; 111: 992–1000.
4.
SundalE., KaeserU.Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis dependent patients.Nephrol Dial Transplant1989; 4: 979–87.
5.
Canadian Erythropoietin Study Group.Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis.Br Med J1990; 300: 573–8.
6.
Canadian Organ Replacement Registry 2002 Preliminary Report.Ottawa: Canadian Institute for Health Information; 2005.
7.
MacdougallI.C., DaviesM.E., HuttonR.D., CavillI., LewisN.P., ColesG.A.The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin.Nephrol Dial Transplant1990; 5: 950–5.
8.
StevensJ.M., AuerJ., StrongC.A., HughesR.T., OliverD.O., WinearlsC.G.Stepwise correction of anaemia by subcutaneous administration of recombinant human erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis.Nephrol Dial Transplant1991; 6: 487–94.
9.
AuerJ., SimonG., StevensJ., GriffithsP., HowarthD., AnastassiadesE.Quality of life improves in CAPD patients treated with subcutaneously administered erythropoietin for anemia.Perit Dial Int1992; 12: 40–2.
10.
KulzerP., SchaeferR.M., KrahnR., SchaeferL., HeidlandA.Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. European Multicentre Study Group.Int J Artif Organs1994; 17: 195–202.
11.
MuirheadN., CattranD.C., ZaltzmanJ., JindalK., FirstM.R., BoucherA.Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction.J Am Soc Nephrol1994; 5: 1216–22.
12.
SalahudeenA.K., KeaveyP.M., HawkinsT., WilkinsonR.Is anaemia during continuous ambulatory peritoneal dialysis really better than during haemodialysis?Lancet1983; 2: 1046–9.
13.
WideroeT.E., SanangenT., HalversenS.Erythropoietin and uremic toxicity during continuous ambulatory peritoneal dialysis.Kidney Int Suppl1983; 16: S208–17.
BoelaertJ.R., SchurgersM.L., MatthysE.G., BelpaireF.M., DaneelsR.F., De CreM.J.Comparative pharmacokinetics of recombinant human erythropoietin administered by the intravenous, subcutaneous and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients.Perit Dial Int1989; 9: 95–8.
16.
IcardiA., PaolettiE., MolinelliG.Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administrations to patients on CAPD.Adv Perit Dial1990; 6: 292–5.
17.
FrenkenL.A., StruijkD.G., CoppensP.J., TiggelerR.G., KredietR.T., KoeneR.A.Intraperitoneal administration of human erythropoietin.Perit Dial Int1992; 12: 78–83.
18.
AbreoK., LubomJ.A., CollierL., FlemingD., WorkJ.Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.Adv Perit Dial1994; 10: 124–8.
19.
BargmanJ.M., JonesJ.E., PetroJ.M.The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate.Perit Dial Int1992; 12: 369–72.
20.
IV NKF-K/DOQI.Clinical practice guidelines for anemia of chronic kidney disease: Update 2000.Am J Kidney Dis2001; 37(Suppl 1): S182–238.
21.
BesarabA., ReyesC.M., HornbergerJ.Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.Am J Kidney Dis2002; 40: 439–46.
22.
CoronelF., HerreoJ.A., MontenegroJ., FernandezC., GandaraA., ConesaJ.Erythropoietin requirements: A comparative multicenter study between peritoneal dialysis and hemodialysis.J Nephrol2003; 16: 697–702.
23.
SnyderJ.J., FoleyR.N., GilbertsonD.T., VoneshE.F., CollinsA.J.Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States.J Am Soc Nephrol2004; 15: 174–9.
24.
TempleR.M., DearyI.J., WinneyR.J.Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis.Nephrol Dial Transplant1995; 10: 1733–8.
25.
BajoM.A., SelgasR., CastroM.J., JiminezC., Fernandez-ReyesM.J., Del PesoG.Erythropoietin treatment decreases cardiovascular morbidity and mortality in CAPD patients.Perit Dial Int1997; 17: 129–35.
26.
BassiS., MontiniG., EdefontiA., PerfumoF., CatterelliD., PiaggioG.Cardiovascular function in a chronic peritoneal dialysis pediatric population on recombinant human erythropoietin treatment.Perit Dial Int1993; 13(Suppl 2): S267–9.
27.
JunorB.J.Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful.Perit Dial Int1993; 13(Suppl 2): S535–7.
28.
HutchisonA.J., OftsthunN.J., HowarthD., GokalR.The effect of hemoglobin concentration on peritoneal mass transfer and drain volumes in continuous ambulatory peritoneal dialysis.Perit Dial Int1992; 12: 230–3.
29.
NavarroJ.F., MaciaM.L., Mora-FernandezC., GallegoE., ChahinJ., MendedM.L.Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients.Adv Perit Dial1997; 13: 257–9.
30.
PageD.E., CheungV., PoirierF.Diabetic patients on peritoneal dialysis need less erythropoietin to maintain adequate hemoglobin.Adv Perit Dial2001; 17: 130–1.
31.
KooistraM.P., MarxJ.J.The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients.Nephrol Dial Transplant1998; 13: 2578–82.
NicolettaP., BernardiniJ., DackoC., TerryC., FriedL.Compliance with subcutaneous erythropoietin in peritoneal dialysis patients.Adv Perit Dial2000; 16: 90–2.
34.
GrzeszczakW., SulowiczW., RutkowskiB., de VecchiA.F., ScanzianiR., DurandP.Y.; European Collaborative Group. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anemia.Nephrol Dial Transplant2005; 20: 936–44.
35.
MacdougallI.C., MathcamJ., GratSJ; ESP 960245/246 Study Group. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.Nephrol Dial Transplant2003; 18: 576–81.
36.
MahajanS., BoultonH., GokalR.A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.J Nephrol2004; 17: 687–92.
37.
TheodoridisM., PassadakisP., KrikiP., PanagoutsosS., YannatosE., KantartziK.Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients.Perit Dial Int2005; 25: 564–9.
38.
LiS., FoleyR., CollinsA.Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States.Kidney Int2004; 65: 1864–9.
39.
LocatelliF., Del VecchioL.Pure red cell aplasia secondary to treatment with erythropoietin.J Nephrol2003; 16: 461–6.
40.
CasadevallN.Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.Nephrol Dial Transplant2003; 18(Suppl 8) viii37–viii41.
41.
BovenK., StrykerS., KnightJ., ThomasA., van RegenmortelM., KenenyD.M.The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.Kidney Int2005; 67: 2346–53.
